Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Publication
Article
Specialty Pharmacy Times
June 2020Volume3 Issue 2
Examining the Use of Immunoglobulin for Primary Immunodeficiency Disorders
This continuing education activity is supported by an educational grant from CSL Behring.
THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM CSL BEHRING.
FACULTY
Luigi Brunetti, PharmD, MPH
Associate Professor of Pharmacy, Co-Director, Center of Excellence in Pharmaceutical Translational Research
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey
At the completion of this activity, the participant will be able to:
- Explain the pathophysiology of common primary immunodeficiency disorders (PIDs)
- Analyze the use of intravenous (IV) and subcutaneous (SC) immunoglobulins for PID, including dosing, efficacy, and unique characteristics of products
- Identify pharmacy considerations for IV and SC initiation, administration, and adverse effect management
TARGET AUDIENCE: Specialty pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: March 30, 2020
EXPIRATION DATE: June 14, 2021
ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours
FEE: This lesson is offered for free at www.pharmacytimes.org.
Articles in this issue
Timely Antiviral Administration for Influenza Is Critical to Reduce Its Clinical and Economic Burden
Relapsed or Refractory Follicular and Mantle Cell Lymphomas: Pharmacist-Driven Strategies to Optimize Patient Management
CIDP Care: A Patient and Clinical Experts Weigh In
Emerging Strategies in the Treatment and Management of Idiopathic Pulmonary Fibrosis
Hereditary Angioedema: Management Updates for the Specialty Pharmacist
JAK Inhibitors Are Important Tools for Patients With Myelofibrosis
Examining the Use of Immunoglobulin for Primary Immunodeficiency Disorders
Hereditary Angioedema: Only Appropriate Pharmacotherapy Reduces Overall Costs
Specialty Pharmacists Have Broad Responsibilities in Chronic Lymphocytic Leukemia
New Agents for Myelodysplastic Syndromes May Reduce Transfusion Requirements
The Multidisciplinary Team Improves Cystic Fibrosis Outcomes
Inflammatory Bowel Disease: Patient-Centered Care for Best Outcomes
Psoriatic Arthritis: Experts Discuss Treatment Responsiveness and Cost
Wet Age-Related Macular Degeneration Treatment Updates and Specialty Pharmacy Considerations
Reviewing Interleukin 17– and Interleukin 23–targeting Therapies and Best Practices in Psoriatic Disease Management Feat. Clinical Practice Video Vignettes
Related Content
